Choose your region
Select the region that best fits your location or preferences.
International
Sverige
Norge
Danmark
Suomi
United Kingdom
Deutschland
France
België
Nederland
Österreich
Schweiz
Italia
España
Choose your site language
This setting controls the language of the user interface, including buttons, menus, and all site text. Select your preferred language for the best browsing experience.
English
English
Swedish
Svenska
Norwegian
Norsk
Danish
Dansk
Finnish
Suomi
German
Deutsch
French
Français
Dutch
Nederlands
Italian
Italiano
Spanish
Español
Choose your job languages
Select the languages for job listings you want to see. This setting determines which job advertisements will be displayed to you.
The two founders still own approximately 75% of the company, the remainder is owned by key persons within the organization. The company is devoted to research and development of bone regenerative technologies and biomaterials. The company is performing early-stage, pre-clinical in vitro and animal studies and all of its inventions are within the field described above. The company’s main assets next to its researchers are its patents and patent applications. Since its inception, the company has successfully developed and licensed out/sold several patent portfolios to major players within the dental implant industry. The Company is focusing all its R & D on its three new technologies, a titanium based ceramic bone graft material (NuBone®), a synthetic peptide family (NuPep™) and a paste for peri-implantitis treatment (NuGel™).